Acalabrutinib Appears More Effective in Earlier Lines of Treatment for CLL
A pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.
Adverse Event Considerations for DARA-VRd in NDMM
Experts on multiple myeloma discuss the safety profile of DARA-VRd in patients with newly diagnosed multiple myeloma.
Long-Term Follow-up with Teclistamab in R/R MM: Updates from MajesTEC-1
Samer Al'Hadidi, MD, provides an overview of recent updates presented at ASCO 2024 from the MajesTEC-1 trial evaluating teclistamab in patients with relapsed/refractory multiple myeloma.
Key Efficacy Data from PERSEUS in Newly Diagnosed Multiple Myeloma
Myeloma specialists provide comprehensive insights on key data from the PERSEUS trial evaluating MRD status in patients receiving DARA-VRd and VRd.
Updates From the Phase 2 MonumenTAL-2 Study Investigating Talquetamab in R/R MM
Hans Lee, MD, discusses recent updates from the MonumenTAL-2 study investigating talquetamab in patients with relapsed/refractory multiple myeloma.
Unmet Needs and Key Takeaways: ECHO Clinical Trial
Medical experts evaluate unmet needs, key insights from the Phase 3 ECHO trial, and potential obstacles in integrating the findings into existing treatment protocols.
Phase 3 ECHO: Safety Data Review
Medical experts analyze and provide insights on safety findings from the Phase 3 ECHO trial, offering their professional interpretations of the data.
Describing the Value of ctDNA in Clinical Practice
The key opinion leaders share their approaches for communicating about circulating tumor DNA and minimal residual disease to patients, emphasizing the significance of ctDNA testing in detecting MRD.
Circulating Tumor DNA Detection Techniques
Experts outline circulating tumor (ct) DNA analysis, detailing the two main techniques and their respective advantages and disadvantages.
Tanya B. Dorff, MD, on Results From Phase 1 CAR T-Cell Therapy mCRPC Trial
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
Improving Access for Patients Receiving CAR T-Cell Therapy
Experts on multiple myeloma provide clinical insights on unmet needs associated with CAR T-cell therapy, focusing on patient access across academic and community settings.
Educating Patients on Complications Associated with CAR T-Cell Therapy
The panel provides clinical insights on talking with patients about complications associated with CAR T-cell therapy.
Assessing the Benefit of CAR T-cell Therapies for mCRPC
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
ASCO 2024 Updates: nccRCC + Chromophobe RCC
Key opinion leaders analyze the latest advancements and research findings specific to Non-Clear Cell Renal Cell Carcinoma presented at the American Society of Clinical Oncology 2024 conference.
TKIs, Disease Progression and Subsequent Therapy in RCC
Key opinion leaders examine the application of tyrosine kinase inhibitors (TKIs) and evaluate first-line therapeutic approaches for renal cell carcinoma.
Determining Resectability and Subsequent Therapy in Pancreatic Cancer
Kamran Idrees, MD, MSCI, MMHC, FACS, discusses how factors such as vessel involvement can influence the decision to proceed with surgical therapy.
Managing Cytopenias and HLH/MAS Following CAR T-Cell Therapy
Continuing the discussion on supportive care strategies, the panel discusses the management of cytopenias and HLH/MAS following CAR T-cell therapy.
Supportive Care Strategies for CAR T-Cell Therapy Recipients
Experts on multiple myeloma provide clinical insights on supportive care strategies for patients experiencing infections or secondary malignancies following CAR T-cell therapy.
Glofitamab Shows Benefit Regardless of Prior BTK Exposure in R/R MCL
All patient populations benefitted from glofitamab in a phase 1/2 trial, but the design excluded capture of high-risk features present in similar studies.
Defining the Attributes of LINACs, IORT in Pancreatic Cancer Care
Milad Baradaran, PhD, DABR, outlines the design of Mobetron as an option for administering intraoperative radiation therapy in pancreatic cancer care.
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD")
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "This series features 2 KOLs.")
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "4 KOLs are featured in this panel.")
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "2 KOLs are featured in this series")
